NCT04793373 is a NA clinical trial of Syringe in Anesthesia, sponsored by Harvard Medical School (HMS and HSDM).

Who is sponsoring NCT04793373?

NCT04793373 is sponsored by Harvard Medical School (HMS and HSDM).

What drugs are being tested in NCT04793373?

Interventions in NCT04793373: Syringe.

What condition does NCT04793373 study?

NCT04793373 studies Anesthesia.

Is NCT04793373 still recruiting?

NCT04793373 is currently withdrawn. Last updated 21 July 2023.

Last reviewed 2023-07-21 · How we verify

NCT04793373

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Superiority of Epidural Placement Technique Using EpiFaith Syringe

Withdrawn NA Last updated 21 July 2023

What this trial tests

NA trial testing Syringe in Anesthesia. Withdrawn.

Timeline

15 May 2022

Primary endpoint
31 December 2025

30 June 2026

Quick facts

Lead sponsor	Harvard Medical School (HMS and HSDM)
Phase	NA
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	health services research
Start date	15 May 2022
Primary completion	31 December 2025
Estimated completion	30 June 2026
Sites	1 location across United States

Drugs / interventions tested

Syringe

Conditions studied

Anesthesia — all drugs for Anesthesia →

Sponsor

Harvard Medical School (HMS and HSDM)

Who can join

18 and older, female only, with Anesthesia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to evaluate the impact of EpiFaith® syringe on the establishment of successful epidural labor analgesia, change of elapsed time for identification of epidural space, and learning curve of CA-1 residents.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Syringe

Trials testing the same drug.

NCT03571516 — Safety, Efficacy and Pharmacokinetic Study of Teduglutide in Infants 4 to 12 Months of Age With Short Bowel Syndrome · Phase 3 · completed
NCT03596164 — An Extension Study of Teduglutide in Japanese Participants With Short Bowel Syndrome Who Completed 24 Weeks of Treatment · Phase 3 · completed
NCT03663582 — Study of Teduglutide in Japanese Participants With Short Bowel Syndrome · Phase 3 · completed
NCT02954458 — Long-term Safety and Efficacy Study of Teduglutide in Pediatric Participants With Short Bowel Syndrome (SBS) · Phase 3 · completed

Other recruiting trials for Anesthesia

Currently open trials in the same condition.

NCT07294092 — Ketamine and Propofol NeuroImaging · EARLY_PHASE1 · recruiting
NCT07290205 — Remimazolam NeuroImaging · EARLY_PHASE1 · recruiting
NCT07465185 — Intrathecal Bupivacaine With or Without Dexmetomidine for Cesserian Delivery · Phase 2 · recruiting
NCT07269808 — Sedation During Endoscopy Using Remimazolam: Efficacy in a Novel Exploration · Phase 3 · recruiting
NCT07443254 — Prospective IR-led Sedation Feasibility · Phase 1, PHASE2 · recruiting

Other Harvard Medical School (HMS and HSDM) trials

Trials by the same sponsor.

NCT07440303 — Star Matrix vs Autogenous Graft for Gingival Augmentation: Split-Mouth RCT · NA · recruiting
NCT07203885 — AI-Assisted Acute Myeloid Leukemia Evaluation With the Leukemia End-to-End Analysis Platform (LEAP) Versus Clinician-Onl · NA · completed
NCT07090863 — Additively Versus Subtractively Manufactured Implant Supported Fixed Dental Prostheses · NA · not yet recruiting
NCT07307157 — Head-to-Head Evaluation of the Cancer Ontology Supervised Multimodal Orchestration (COSMO) AI System Versus Pathologist- · enrolling by invitation
NCT06651502 — Efficacy of a Dental Implant System for Immediate Restoration · NA · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04793373 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Harvard Medical School (HMS and HSDM)
Last refreshed: 21 July 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04793373.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing